Profile data is unavailable for this security.
About the company
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
- Revenue in USD (TTM)0.00
- Net income in USD-75.08m
- Incorporated2018
- Employees14.00
- LocationInstil Bio Inc3963 Maple Avenue, Suite 350DALLAS 75219United StatesUSA
- Phone+1 (972) 499-3350
- Fax+1 (302) 531-3150
- Websitehttps://instilbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc | 0.00 | -42.10m | 47.49m | 26.00 | -- | -- | -- | -- | -3.45 | -3.45 | 0.00 | -1.50 | 0.00 | -- | -- | 0.00 | -51.87 | -36.08 | -61.53 | -39.62 | -- | -- | -- | -870.34 | -- | -- | -- | -- | -100.00 | -- | 57.74 | -- | -67.85 | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 47.77m | 2.00 | -- | -- | -- | 1,910.80 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 47.96m | 75.00 | -- | -- | -- | 224.10 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 48.49m | 21.00 | -- | 6.85 | -- | 9.22 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Lipocine Inc | 4.32m | -5.48m | 48.91m | 16.00 | -- | 3.38 | -- | 11.32 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 49.23m | 75.00 | -- | 0.3827 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 50.43m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 50.67m | -- | -- | 6.33 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 52.15m | 14.00 | -- | 0.4331 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Cingulate Inc | 0.00 | -22.06m | 52.52m | 13.00 | -- | 11.74 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 52.53m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 52.82m | 2.00 | -- | -- | -- | 218.28 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 56.55m | 146.00 | -- | 0.3927 | -- | 6.71 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 56.79m | 32.00 | -- | 0.8254 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Instil Bio Inc's reporting currency: US Dollar USD
28.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2025 | 645.60k | 9.52% |
| CPMG, Inc.as of 30 Sep 2025 | 410.92k | 6.06% |
| Millennium Management LLCas of 30 Sep 2025 | 196.74k | 2.90% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 166.97k | 2.46% |
| Sectoral Asset Management, Inc.as of 30 Sep 2025 | 161.38k | 2.38% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 97.90k | 1.44% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 74.89k | 1.10% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 60.96k | 0.90% |
| Boxer Capital Management LLCas of 30 Sep 2025 | 60.70k | 0.90% |
| Nomura Investment Management Business Trustas of 30 Sep 2025 | 50.00k | 0.74% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
